A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
NCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT Number: NCT02248909
This study is an observational multicenter descriptive study. The study will be conducted in primary outpatient medical institutions in different cities of the RF. Primary care doctors who are primary contact for greater part of the population in RF including COPD patients will be invited as investigators. This observational descriptive study will be conducted within the routine practice of outpatient institutions. Since spirometry is not an integral part of the current all-round clinical practice, only those sites where spirometry test is routinely used in examination of patients with COPD risk factors and when monitoring condition of COPD patients will take part in the study. Thus the decision about spirometry in every study subject will be determined only by the existing treatment approaches.
Looking for future studies?
Notify MeAll sexes
Observational
Research Site, Barnaul, Nis-rru-xxx-2014/2, Russia
The study is an observational multicenter descriptive study. No hypothesis is checked in the study.
3000 patients with COPD risk factors are planned to be enrolled into the study (current smokers and former smokers with smoking history of ≥10 pack/years at the age of >40 years who have respiratory complaints) and 1450 patients previously diagnosed with COPD who contacted the physicians of outpatient institutions during the study (for 3 months) and are currently in remission.
100 patients with COPD risk factors and approximately 50 patients early diagnosed with COPD currently being stable are planned to be enrolled in each site.
Physicians and pulmonologists of the outpatient institutions of the Russian Federation will take part in the study in about 30 sites in 18 cities (a total of 31% of RF population live in the cities).
The observational descriptive study will be conducted within the routine practice of outpatient institutions. Examining and treatment of patients will be performed according to the rules of the routine practice.
Patients will be enrolled into the study as they visit the outpatient institutions for the medical care. The study does not imply any special invitation of COPD patients to the sites for them to be enrolled into the study. Therefore the conditions are made for the study population to reflect the typical visitors of the primary care medical institutions in different RF (Russian Federation) regions. Patients are enrolled into the study regardless the reason for appointment with a doctor. A reason for the appointment can be respiratory complaints as well as any other diseases or certificates and conclusions. To be enrolled into the study the subjects must sign the written Informed Consent Form (ICF) to participate in the study and to use personal data confidentially.
To investigate the role of spirometry in diagnostics and management of the COPD patients, two groups of patients are supposed to be included into the study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Patients with COPD risk factors must meet all the following inclusion criteria:
Patients with previously diagnosed COPD must meet all the following inclusion criteria:
Exclusion criteria
for patients with COPD risk factors:
Patients with previously diagnosed COPD must meet all the following inclusion criteria:
Time frame: Up to 5 months
Time frame: Up to 5 months
Time frame: Up to 5 months
Time frame: Up to 5 months
Time frame: Up to 5 months
Time frame: Up to 5 months
Time frame: Upto 5 months
Time frame: Up to 5 months
Time frame: Up to 5 months
AstraZeneca
Industry
Non-interventional Multicenter Study of Spirometry Use to Diagnose COPD and to Prescribe Treatment to COPD Patients in the Outpatient Institutions of the healthcaRe System of the Russian FederaTion
Acronym: SUPPORT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03927820
Asthma, Bronchial Diseases
Nashville, Tennessee, United States
View Trial DetailsNCT06614959
Bronchial Diseases, Bronchitis
Montreal, Quebec, Canada
View Trial DetailsNCT04754490
COPD, Chronic Disease
Abercynon, Wales, United Kingdom
View Trial DetailsNCT06336252
Arthritis, Basal Ganglia Diseases
Copenhagen, Denmark
View Trial Details